Regenerating Insulin-Producing Cells: What Preclinical Research Reveals About a New T1D Strategy

Type 1 diabetes occurs when the immune system attacks and destroys the pancreas's insulin-producing beta cells. This loss of cells leads to high blood sugar levels that require management. Today, insulin replacement therapy is the first-line treatment—patients inject or infuse insulin to maintain safe blood sugar levels.

Other options exist but are available to only a small number of people. Islet transplantation—moving healthy beta cells from a donor—is one approach, and stem cell-derived islet therapies are currently in clinical trials. Additionally, newer immunotherapy drugs can slow or delay beta-cell destruction, giving the pancreas's remaining cells a better chance to survive.

Even after a T1D diagnosis, the pancreas retains some functioning beta cells. Researchers believe that if these remaining cells could be coaxed to multiply and regenerate, the pancreas might restore its own insulin production. This approach differs from replacing beta cells through transplant—instead, it aims to unlock the body's natural capacity to heal itself.

Successful beta-cell regeneration could restore the pancreas's ability to sense blood sugar changes and respond appropriately, potentially leading to more stable and natural blood sugar control than insulin therapy alone provides.

A new review of preclinical studies identified 14 distinct biological targets or mechanisms that appear to promote beta-cell multiplication in laboratory and animal models. These targets represent different ways scientists might stimulate the pancreas to grow new insulin-producing cells.

One target, a protein called DYRK1A, has emerged as particularly well-validated. Multiple research teams have studied small-molecule drugs that inhibit DYRK1A, and animal studies suggest this approach can trigger beta-cell proliferation. This convergence of evidence—from lab work to animal models—makes DYRK1A a leading candidate for future drug development.

Beta-cell regeneration therapies remain in preclinical stages, meaning they have been tested in cells and animals but not yet in patients. Before any regenerative approach reaches clinical trials, researchers must refine drug development, optimize dosing strategies, and confirm that such therapies work safely alongside existing T1D treatments like immunotherapy and insulin.

The review emphasizes that translating these findings into viable medicines will require careful attention to how regenerative approaches complement rather than compete with current therapeutic options. Success could eventually offer T1D patients a new class of treatment aimed at restoring the pancreas's own insulin production.

Source: Diabetic medicine : a journal of the British Diabetic Association. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.